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Th17 Cells and Rheumatoid Arthritis
―From the Standpoint of Osteoclast
Differentiation―
Kojiro Sato1
ABSTRACT
Rheumatoid arthritis is a chronic disease that affects multiple joints. It is considered to be an autoimmune dis-
ease in which a T helper (Th)-1 type response has been implicated to play an important pathogenetic role. As
osteoclasts, cells that resorb bone, play a crucial part in the bone destruction that occurs in RA, we and others
have investigated the pathophysiology of these cells. The findings that interferon (IFN)-γ strongly inhibits osteo-
clastogenesis and that interleukin (IL)-17 has the ability to enhance osteoclast differentiation have cast doubt
on the hypothesis that RA is a Th1 disease. In this review, I describe the relationship between Th cells, the so-
called “commander” of the immune response, and RA, mainly from the viewpoint of the environments Th cells
create for the excessive differentiation and function of osteoclasts, resulting in the destruction of bone.
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INTRODUCTION: WHAT ARE OSTEO-
CLASTS?
Osteoclasts are specially differentiated giant multinu-
clear cells of monocytemacrophage lineage, which
decompose bone matrix such as hydroxyappatite and
collagen by producing various proteases and acids.
These cells have gathered much attention lately be-
cause abnormal functions of the cells can lead di-
rectly to various clinical problems. In the normal
bone, a proper balance is maintained between bone
formation by osteoblasts and bone resorption by os-
teoclasts. If osteoclasts overfunction, however, bone
destruction, as is observed in rheumatoid arthritis
(RA) and osteoporosis, may occur. On the other
hand, reduced activity of osteoclasts causes a heredi-
tary disease called osteopetrosis (Fig. 1a).1 Bisphos-
phonates, now used in clinical fields as therapeutic
agents for osteoporosis, inhibit both osteoclast differ-
entiation and function, and hence ameliorate osteopo-
rosis.2
As is explained in more detail later, several sets of
experimental data have shown that “there is no bone
destruction of RA without osteoclasts.” Thus, in order
to have insight into the pathogenesis of RA, we have
tried to understand the conditions in which excessive
osteoclastogenesis occurs.
Recently, understanding on osteoclasts has grown
rapidly. The identification of the osteolcast differen-
tiation factor has served as the main driving force in
this advance. Suda and colleagues revealed that os-
teoclasts can be differentiated in vitro by co-culturing
osteoclast precursor cells (monocytemacrophage
lineage cells) with osteoblasts or stromal cells de-
rived from the bone marrow in the presence of vita-
min D,3,4 indicating that osteoblasts produce certain
osteoclast differentiation factor(s). About 10 years
later, the factor was identified by two independent
groups as osteoclast differentiation factor (ODF), or
osteoprotegerin ligand (OPGL), respectively.5,6 Using
this cytokine and another cytokine, macrophage
colony-stimulating factor (M-CSF), a survival factor
for macrophagemonocyte lineage cells, it is now
possible to differentiate osteoclasts in vitro without
the help of osteoblasts. Thus, biochemical analysis
with pure osteoclasts was made possible, leading to
the recent rapid progress in this field (Fig. 1b).
Interestingly, this TNF family cytokine ODF
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Fig. 1 Dysfunction of osteoclasts directly leads to diseases. (a) In the nor-
mal body, there is a proper balance between osteoblasts that produce bone 
and osteoclasts that resorb it. If osteoclasts do not function appropriately, os-
teopetrosis, usualy a congenital disease, occurs, while if osteoclasts overfunc-
tion, osteoporosis or pathological bone destruction, as observed in rheumatoid 
arthritis, may ensue. (b) Osteoclast precursor cels diferentiate into mature os-
teoclasts in the presence of supporting cels of osteoclastogenesis, such as os-
teoblasts and stromal cels. They provide the precursor cels with two 
cytokines, RANKL and M-CSF. We can now obtain mature osteoclasts in vitro 
without the help of osteoblasts by adding RANKL and M-CSF to the culture 
system. RANK: receptor activator of NF-κB
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OPGL was found to be identical to the cytokine called
receptor activator of NF-κB ligand (RANKL), or TNF-
related activation-induced cytokine (TRANCE),
which had been reported to be expressed on T lym-
phocytes the previous year. RANKL has been demon-
strated to be expressed on activated T cells and could
thus contribute to the activation of dendritic cells that
express its receptor (RANK). Thus, activated T cells
have been implicated to also stimulate osteoclast pre-
cursor cells and promote osteoclastogenesis.
RHEUMATOID ARTHRITIS AND OSTEO-
CLASTS
This finding is particularly important for understand-
ing the pathogenesis of RA. RA is a disease in which
multiple joints are damaged by inflammation. Bone
and cartilage destruction in the course of persistent
inflammation is a serious clinical problem. It is con-
sidered to be one of autoimmune diseases, and the
activation of T cells recognizing autoantigens is impli-
cated in the pathogenesis. T helper (Th) cells that are
“conductors” of the immune response have been di-
vided into 2 subsets (Th1 and Th2) (Fig. 2). The for-
mer is the subset responsible for the deprivation of
intracellular pathogens such as viruses from the
body, and the latter is essential for the protection of
the body from extracellular pathogens such as nema-
todes. RA for some time now has been believed to be
a disease in which the Th1Th2 balance is skewed to
Th1.7 Interferon (IFN)-γ and interleukin (IL)-2, the
key cytokines produced from Th1 cells, however,
were reported to be barely detected in the affected
joints of RA patients.8,9 Moreover, IFN-γ receptor-
deficient mice exhibited more severe bone destruc-
tion in a mouse collagen-induced arthritis (CIA)
model that is an animal model of RA,10,11 suggesting
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Fig. 2 Schematic diagram of Th1 and Th2 diferentiation. Naive T helper 
cels (Thps) stimulated by antigen-presenting cels (APCs) diferentiate into 
either Th1 or Th2 cels, depending on the cytokine profile of the 
environments. Each subset releases specific cytokines, which inhibit the dif-
ferentiation of the other subset. As for the provider of IL-4 that is essential 
to Th2 diferentiation, several cels are assumed to play the role, including 
the Th2 cels themselves.
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that RA is not in fact a Th1 disease.
The following experimental data indicate that os-
teoclasts are required in the bone destruction ob-
served in arthritis models. (1) Inflammation was ob-
served in RANKL deficient mice upon transferring se-
rum containing anti-glucose-6-phosphate isomerase
antibody (an arthritis model of serum transfer12),
however, significantly less bone destruction was ob-
served compared to that in wild type mice.13 (2) The
bone destruction in adjuvant-induced arthritis was in-
hibited by treating the study rats with the inhibitor of
RANKL, osteoprotegerin (OPG).14 These findings led
to the conclusion that “there is no bone destruction
without osteoclasts.” In the latter report, Kong et al.
showed that the RANKL on activated T cells directly
acts on osteoclast precursor cells and induces osteo-
clast differentiation. By the same token, Horwood
and his colleagues reported that activated T cells
could induce osteoclast differentiation in vitro.15 How-
ever, we have to take into consideration the facts that
the T cells used by Kong et al. were fixed with forma-
lin, and therefore the effects of humoral factors might
be neglected, and that the T cells used by the latter
group were derived from humans while the osteo-
clast precursor cells were from mice, making their
system a cross-species co-culture system.
IFN-γ STRONGLY INHIBITS OSTEOCLAST
DIFFERENTIATION-CONTRADICTION TO
THE TH1 HYPOTHESIS OF RA
Takayanagi and colleagues reported that IFN-γ,
which is a representative cytokine of Th1 response,
strongly suppressed osteoclast differentiation,16 a
finding contradicting the theory of Kong’s group in
case that RA is really a Th1-type disease.
In order to settle the issue, we decided to examine
if there are any Th subsets that actually promote os-
teoclast differentiation. As described above, osteo-
clasts can be obtained in vitro by culturing mice os-
teoclast precursor cells along with osteoblasts (the
co-culture system), and also by culturing the precur-
sor cells alone, first in the presence of M-CSF and
then with M-CSF and RANKL (the RANKLM-CSF
system). When we added Th1 or Th2 cells to those
culture systems, both Th12 cells strongly inhibited
osteoclastogenesis.17 CD25+CD4+ T cells, which have
received much attention lately as regulatory T cells,
did not suppress osteoclast differentiation, but did not
enhance osteoclastogenesis either. Thus, the Th sub-
sets that were known at the time could not promote
osteoclast differentiation.
IL-17-PRODUCING TH CELLS ENHANCE
OSTEOCLAST DIFFERENTIATION-THE DIS-
COVERY OF TH17 SUBSET IN THE CON-
TEXT OF “OSTEOIMMUNOLOGY”
We then took notice of a report in which Th cells
stimulated by IL-23 produce IL-17.18 One reason is
that Kotake and his colleagues reported that IL-17
was detected in the synovial fluid from RA patients
and that it enhanced osrteoclastogenesis in vtiro.19
Another reason is that IL-23 is a heterodimer cy-
tokine that shares p40 subset with IL-12, which is es-
sential to Th1 differentiation.20 We hypothesized that
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Fig. 3 The IL-23-IL-17 axis plays an important role in 
pathological bone resorption. Histological examination of cal-
varia bones of wild type (WT), Il17－/－, Il23a－/－ and Ifngr1－/－
Stat6－/－ mice treated with LPS. Bone destruction was less 
severe in Il17－/－ and Il23a－/－ mice. Interestingly, more se-
vere bone destruction was observed in Ifngr1－/－Stat6－/－ mi-
ce, which are supposed to have a defect in both Th1 and 
Th2 diferentiation, indicating that the Th1 and Th2 re-
sponses ameliorate and the Th17 response enhances patho-
logical bone resorption.
WT Il17a－/－
Ifnr1－/－Stat6－/－Il23a－/－
by using IL-23 instead of IL-12, we might be able to
differentiate Th cells that produce IL-17 but not IFN-γ
or IL-4. We stimulated Th cells in the presence of IL-
23, anti-IFN-γ Ab and anti-IL-4 Ab and obtained the
specific cells that produced a large amount of IL-17
but little IFN-γ or IL-4, as we had expected. When we
added the cells to the co-culture system of osteoclast
differentiation, we were able to enhance osteoclasto-
genesis for the first time.17 In 2005, a new Th subset
was reported by two independent groups,21,22 which
is now widely known as Th17, and the method of dif-
ferentiating the cells was almost the same as that
used by us. We not only performed in vitro experi-
ments but also in vivo experiments, and showed that
the bone destruction induced by local administration
of lipopolysaccharide (LPS) was greatly reduced in
both IL-17 deficient mice and IL-23 deficient mice
compared to WT mice (Fig. 3). We also showed that
in the synovium from RA patients, the expression of
RANKL and that of IL-23 (p19 subset and p40 subset)
correlated positively, but that those of RANKL and IL-
12 (p35 subset) did not (Fig. 4). Thus, we had sought
Th subsets that can enhance osteoclastogenesis and
encountered the new Th subset, Th17. This was in-
deed an exciting development and our report first in-
dicated the significance of Th17 in the pathogenesis
of the bone destruction in RA.23,24
In 2006, it was reported that IL-6 and TGF-β con-
tributed more to mouse Th17 differentiation than IL-
23, and that IL-23 was a growth factor rather than a
differentiation factor25,26; however, there is still con-
troversy (See the “Future tasks” section).
One of the mechanisms by which Th17 stimulates
osteoclastotgenesis is through RANKL induction of
osteoblasts via IL-17 signaling.19 As for the contribu-
tion of the RANKL on T cells, Th17 cells did express
more RANKL on their surface than Th1 cells but they
could not differentiate osteoclasts in the absence of
exogenously-added soluble RANKL. Thus, we believe
that, at least in our culture system, the RANKL on T
cells alone is not sufficient for osteoclastogenesis
(Fig. 5).17 In order to truly examine the hypothesis of
Kong et al. described above, we will have to wait for
the generation of T-cell specific RANKL deficient
mice.
FUTURE TASKS
We mainly used cells derived from mice for our ex-
periments and so did the early reports of Th17 cells.
Similar IL-17 producing cells have been also discov-
ered in human, but their differentiation factors are re-
ported to be IL-1 and IL-6, instead of IL-6 and TGF-β.
In fact, TGF-β had the opposite effect of suppressing
human Th17 cell differentiation,27,28 indicating a clear
species difference. It is always necessary to take
these species differences into consideration, and also
carefully examine the difference between Th17 cells
differentiated in vitro and IL-17 producing Th cells in
vivo.
One of the characteristics of Th1Th2 subsets is
their exclusivity; Th1 cells inhibit Th2 differentiation
by secreting cytokines and vice versa. This tendency
is also observed among Th1217 cells.21,22,29 As this
has the structural form of a positive feedback mecha-
nism, microscopically, one of the Th subsets is likely
to achieve dominance under sptcific conditions. How-
ever, it is unlikely that all of the cells infiltrating into
synovium of an RA patient are Th17 cells, because
IFN-γ can be detected in the synovial fluid of these
patients, albeit at a very low level. Considering the
fact that Th1- and Th2-type cytokines inhibit osteo-
clast differentiation even at a very low level, does the
distribution of Th1217 cells in inflammatory
synovium constitute a mosaic pattern? This is an in-
triguing question in terms of immunopathology. Also,
there may be a distinct chronological sequence of
Th1217 development in the course of RA develop-
ment. Concerning this, the study of Jacob and his col-
leagues is highly thought-provoking; they showed
that adjuvant arthritis was worsened when IFN-γ was
given 24 hours before administration of the adjuvant,
but that the arthritis was ameliorated when the same
cytokine was given 24 to 48 hours after immunization
with adjuvant, suggesting that IFN-γ may be both
Th17 Cells and Rheumatoid Arthritis
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Fig. 4 RANKL expression corelates with that of IL-23 but not of IL-12 in the synovium of RA patients. 
The relative mRNA expression of RANKL, IL-23A, IL-12A, and IL-12B were standardized using the ex-
pression of GAPDH. Note that the RANKL expression positively corelates with that of IL-23A and IL-12B 
(that constitute the IL-23 heterodimer together) but not with that of IL-12A (that constitutes the IL-12 het-
erodimer with IL-12B).
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Fig. 5 Model of Th17-mediated bone destruciton in rheumatoid arthritis. Th17 
cels release IL-17, which acts on osteoclastogenesis-supporting cels such as 
synovial fibroblasts and make them express RANKL. On the contrary, both Th1 
and Th2 cels inhibit osteoclast diferentiation by releasing IFN-γ and IL-4, 
respectively. In our experimental system, RANKL expressed on Th17 cels alone is 
not suficient for the induction of osteoclast diferentiation. In mice, IL-23 is now 
thought to be a growth factor rather than a diferentiation factor and IL-6 and TGF-β 
are considered to be diferentiation factors. In humans, however, IL-1, instead of 
TGF-β, is implicated in the diferentiation of Th17 cels.
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beneficial and harmful to RA patients depending on
the timing of its administration.30
Since a great deal of attention is now focused on
the relationship between this new Th subset Th17
and RA, it is expected that data of Th1217 profile
using clinical samples from RA patients will be in
hand in the near future. And these results will, with-
out doubt, contribute much to our understanding of
RA and the development of better treatment strate-
gies.
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